Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Josephson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2013
The hemophilias and their clinical managementNeil Josephson
Methods in Enzymology|March 9, 2002
Gene transfer with foamy virus vectorsGrant Trobridge, George Vassilopoulos, Neil Josephson, et al.
Journal of Clinical Apheresis|December 20, 2015
Preoperative management of factor XI deficiency with therapeutic plasma exchange: A case report and literature reviewMonica B Pagano, Barbara A Konkle, Yanyun Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Improved foamy virus vectors with minimal viral sequencesGrant Trobridge, Neil Josephson, George Vassilopoulos, et al.
Leukemia Research|March 21, 2016
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotinUma Borate, Amitkumar Mehta, Vishnu Reddy, et al.
The Oncologist|December 10, 2017
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven CasesCostantine Albany, Lawrence Einhorn, Lawrence Garbo, et al.
Journal of Medical Economics|October 31, 2018
Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphomaThomas E Delea, Arati Sharma, Aaron Grossman, et al.
Cellular Immunology|January 18, 2016
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A miceSriram Krishnamoorthy, Tongyao Liu, Douglas Drager, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology|February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Hematology. American Society of Hematology. Education Program|December 10, 2013
The hemophilias and their clinical managementNeil Josephson
Methods in Enzymology|March 9, 2002
Gene transfer with foamy virus vectorsGrant Trobridge, George Vassilopoulos, Neil Josephson, et al.
Journal of Clinical Apheresis|December 20, 2015
Preoperative management of factor XI deficiency with therapeutic plasma exchange: A case report and literature reviewMonica B Pagano, Barbara A Konkle, Yanyun Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Improved foamy virus vectors with minimal viral sequencesGrant Trobridge, Neil Josephson, George Vassilopoulos, et al.
Leukemia Research|March 21, 2016
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotinUma Borate, Amitkumar Mehta, Vishnu Reddy, et al.
The Oncologist|December 10, 2017
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven CasesCostantine Albany, Lawrence Einhorn, Lawrence Garbo, et al.
Journal of Medical Economics|October 31, 2018
Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphomaThomas E Delea, Arati Sharma, Aaron Grossman, et al.
Cellular Immunology|January 18, 2016
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A miceSriram Krishnamoorthy, Tongyao Liu, Douglas Drager, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology|February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Pageof 1